PTD-DBM

Identity and composition

PTD-DBM is a synthetic fusion peptide which is studied in preclinical research as a disruptor of the interaction between the CXXC5 and Dishevelled (Dvl) proteins, in order to modulate Wnt/beta-catenin signaling in skin. It is designed for experimental use in dermatology (cutaneous wound healing and hair follicle neogenesis).

Its full name corresponds to Protein Transduction Domain-fused Dishevelled Binding Motif, and it is also identified as CXXC5-Dvl competitor peptide o CXXC5-Dishevelled disruptor peptide. Structurally it combines a protein transduction domain (PTD) that facilitates cellular and skin penetration, a flexible linker and a Dishevelled binding motif (DBM); some constructs are conjugated with lysine-FITC for visualization.

As for its chemical identity constants (CAS number, molecular weight, molecular formula, and sequence), no confirmed values are available in reference databases such as PubChem or DrugBank, so they are described qualitatively and no specific figures are reported.

Product for research use.

Mechanism of action

The proposed mechanism of PTD-DBM focuses on the signaling pathway Wnt/beta-catenin, relevant in processes of proliferation, healing, and hair follicle development.

The protein CXXC5 acts as a negative feedback regulator of this pathway: it binds to Dishevelled (Dvl) and halts Wnt signaling. PTD-DBM is designed to competitively displace CXXC5 from its binding with Dvl, thereby releasing the inhibition and reactivating Wnt/beta-catenin signaling.

In in vitro assays, the disruption of the Wnt3a-induced CXXC5-Dvl-1 interaction was associated with dose-dependent increases in markers such as beta-catenin, alpha-SMA and collagen I, as well as with fibroblast migration and collagen gel contraction, with effects comparable to those of Wnt3a or TGF-beta (PMID 26056233). In models of skin and hair follicle, the disruption of the CXXC5-Dishevelled interaction with a competitor peptide was related to the activation of Wnt/beta-catenin and stimulation of the growth and neogenesis of the hair follicle, in line with what was observed in CXXC5-/- mice (PMID 28595998).

The peptide's PTD aims to favor its transdermal and intracellular delivery for topical application in the experimental context.

Pharmacokinetics

No formal pharmacokinetic parameters are available for PTD-DBM. In the reviewed primary literature, no values were reported for half-life, Cmax, or clearance.

Qualitatively, the PTD component of the peptide was incorporated with the intention of promote transdermal and intracellular penetration in experimental topical applications; however, there are no quantitative data on absorption or exposure available. Therefore, any pharmacokinetic characterization must be considered pending and outside the scope of the current evidence.

Scientific evidence

The available evidence on PTD-DBM is preliminary and of a preclinical/experimental nature. Limited to in vitro assays (human dermal papilla cells, fibroblasts, and keratinocytes) and to mouse models.

In preclinical studies, its role has been investigated in two main contexts: healing of skin wounds (PMID 26056233) and androgenic-type hair loss / hair follicle neogenesis (PMID 28595998), typically by means of topical application and frequently in combination with valproic acid. The preliminary evidence suggests that the disruption of the CXXC5-Dishevelled interaction is associated with the activation of the Wnt/beta-catenin pathway in these models.

It is important to note the limits of this evidence: there are no registered human efficacy clinical trials on ClinicalTrials.gov, nor identified IND/NDA processes. It should be considered a compound in the research stage, not an approved or clinically validated treatment.

Research applications

Product for research use.

Ideal for (in a research context):

• In vitro studies of the pathway Wnt/beta-catenin and of the protein-protein interaction CXXC5-Dishevelled.
• Preclinical research in models of skin healing and of hair follicle biology / neogenesis (as studied in in vitro and mouse models).
• Combination assays with activators of the Wnt pathway (e.g. valproic acid) to explore complementary effects on signaling.
• Experimental work with formulations of topical application that take advantage of the protein transduction domain.

Not applicable for:

• clinical use, therapeutic use, diagnostic or cosmetic of any kind.
• Clinical use or self-administration: it has no human efficacy trials or regulatory approval.
• Any application outside a research environment controlled by trained personnel.

Research protocols

The available studies were carried out in in vitro and mouse models, mainly through topical application of the peptide, frequently in combination with valproic acid (an activator of the Wnt pathway through GSK3beta inhibition) to explore a complementary effect.

In the primary literature reviewed, in the in vitro assays, effects were described dose-dependent on pathway markers; however, no validated and transferable numerical dosing scheme is available from the consulted literature, so no specific figures for dose, concentration, or frequency are reported.

The value of 5 mg corresponds to the product presentation and does not represent a recommended study dose. Any experimental protocol must be designed in accordance with the consultable primary literature and the practices of the laboratory.

Reconstitution

As a general laboratory handling guide for lyophilized peptides, reconstitution is usually performed with bacteriostatic water (water for injection with approximately 0.9% benzyl alcohol), which helps limit microbial growth in preparations intended for experimental handling.

General technique recommendations:

• Add the diluent slowly, letting it run down the wall of the vial, without injecting it directly onto the powder.
• Do not shake; swirl gently (rotation) until fully dissolved to reduce mechanical stress on the peptide.
• Let stand until a clear solution is obtained; do not use if it remains cloudy or with particles.
• The diluent volume is chosen according to the working concentration desired for the 5 mg presentation.

These indications are of a general laboratory nature and do not constitute a clinical protocol.

Stability and storage

As a laboratory handling standard for peptides:

• Lyophilized product (powder): is the most stable form. It is usually stored at freezing and protected from moisture and light during prolonged storage; many peptides tolerate short periods at room temperature during transport. - Reconstituted product (in solution): is less stable. It is recommended to keep it at refrigeration for short-term use and in freezing if longer-term storage is required.

General good practices:

• Avoid repeated freeze-thaw cycles; it is advisable to divide into aliquots. - Protect from light and moisture, and keep the vials tightly closed. - Label with the reconstitution date.

These are standard qualitative guidelines; there are no specific stability data for PTD-DBM in the literature consulted.

Safety profile

The safety data for PTD-DBM are limited and exclusively preclinical, so its profile should be interpreted with caution.

In a mouse study, topical application for up to six months was not associated with abnormal cutaneous phenotypes or with an increase in oncogenic markers (such as c-Myc or cyclin D1) in that model (PMID 26056233). This finding is limited to the experimental conditions described.

Important limits and considerations:

• There are no safety, toxicology, or long-term exposure data in humans.
• Since the mechanism reactivates the Wnt/beta-catenin pathway —implicated in cell proliferation and in some tumor processes—, there is a theoretical concern of proliferative risks with chronic systemic exposure that has not been characterized.
• No clinical contraindications are described, as this is a compound in the research stage, without validated clinical use.

This profile reinforces that the material is for research use and not for clinical use.

Comparative context

Within its class of disruptors of the CXXC5-Dishevelled interaction, PTD-DBM represents the topically applied peptide agent.

They have been described separately small-molecule inhibitors targeting the same Dvl-CXXC5 interaction, proposed as candidates in other contexts (for example, anabolic bone therapy for osteoporosis). These represent a alternate chemotype which targets the same protein-protein interaction, but with a chemical nature different from that of the peptide.

In addition, PTD-DBM is frequently studied in combination with valproic acid, which activates the Wnt/beta-catenin pathway downstream through inhibition of GSK3beta. This indicates a complementary or additive effect on the pathway, by acting on a distinct node, rather than on the same point of the signaling.

History and development

PTD-DBM was developed by the research group of Kang-Yell Choi, in the Yonsei University (South Korea), as a tool to modulate the Wnt/beta-catenin pathway through disruption of the CXXC5-Dishevelled interaction.

Its characterization rests on two main works: a 2015 study in which the peptide was defined as a PTD + linker + DBM fusion capable of interfering with the CXXC5-Dvl-1 interaction in the context of skin wound healing (PMID 26056233), and a 2017 study focused on the stimulation of hair growth and wound-induced hair follicle neogenesis (PMID 28595998).

As of the reviewed evidence, it remains a compound at the research stage, with no registered human efficacy clinical trials or identified regulatory approvals.

FAQ

Customer reviews

Average rating: 5.0 out of 5, based on 1 customer rating.

Scientific references (4)

Peer-reviewed literature on PTD-DBM, with its PubMed identifier when available:

• Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis (Lee, et al. · Journal of Investigative Dermatology · 2017) PMID 28595998.
• The Negative Regulator CXXC5: Making WNT Look a Little Less Dishevelled (Kim, et al. · Journal of Investigative Dermatology · 2017) PMID 28967390.
• Blockade of CXXC5-dishevelled interaction inhibits adipogenic differentiation, obesity, and insulin resistance in mice. (Seo SH, et al. · Sci Rep · 2022) PMID 36450849.
• CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD(2). (Ryu YC, et al. · Cells · 2023) PMID 36831222.

Other related research peptides

• TB-500
• TB-500 FRAG
• ACE-031
• ARA-290
• BPC-157
• BPC-157 + TB-500
• BPC-157 + TB-500 + KPV
• KPV